168
Participants
Start Date
January 28, 2020
Primary Completion Date
May 31, 2023
Study Completion Date
October 30, 2024
Futibatinib
Futibatinib 20mg once daily on a 28 day cycle
Futibatinib plus Fulvestrant
Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
Ospedale E. Agnelli, Pinerolo
Istituto Europeo Di Oncologia - IEO, Milan
University Gregorio Marañon, Madrid
START Madrid - CIOCC, Madrid
Mayo Clinic - FL, Jacksonville
Florida Cancer Specialists, Tallahassee
Florida Cancer Specialists, West Palm Beach
Moffitt Cancer Center, Tampa
Florida Cancer Specialists, St. Petersburg
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, Nashville
Tennessee Oncology, Chattanooga
Mayo Clinic - MN, Rochester
Azienda Ospedaliero Universitaria Pisana, Pisa
HCA Midwest Health, Kansas City
Centre Leon Berard, Lyon
UT Southwestern, Dallas
MD Anderson, Houston
Mayo Clinic - AZ, Phoenix
USCF, San Francisco
Institut Gustave Roussy, Villejuif
AOU Policlinico - Vittorio Emanuele, Catania
Massachusetts General Hospital, Boston
BIDMC, Boston
Dana Farber Cancer Institute, Boston
Tom Baker Cancer Center, Calgary
SunnyBrook Health Sciences, Toronto
AOU Modena Policlinico, Modena
Istituto Nazionale Tumori Regina Elena, Roma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Centro Hospitalar Universitario Lisboa Norte, Lisbon
Porto University, Porto
Instituto Portugues de Oncologia do Porto, Porto
Vall d'Hebron, Barcelona
HCA Healthcare UK, London
The Christie NHS Foundation Trust, Manchester
The Royal Marsden NHS Foundation Trust, Sutton
Taiho Oncology, Inc.
INDUSTRY